###begin article-title 0
Impact of Caveolin-1 Expression on the Prognosis of Transitional Cell Carcinoma of the Upper Urinary Tract
###end article-title 0
###begin p 1
###xml 528 529 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 548 549 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 699 700 699 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 579 587 <span type="species:ncbi:9606">patients</span>
###xml 657 665 <span type="species:ncbi:9606">patients</span>
This study aimed to investigate the relationship of caveolin-1 expression with prognosis in patients with transitional cell carcinoma of the upper urinary tract (TCC-UUT). Formalin-fixed, paraffin-embedded tissue sections of TCC-UUT from 98 patients, who had undergone radical nephroureterectomy, were stained immunohistochemically using antibodies against caveolin-1. The expression pattern of caveolin-1 was compared with the clinicopathological variables. The caveolin-1 expression was significantly correlated with T stage (p<0.001) and grade (p=0.036). The survival rate of patients with caveolin-1 positive tumors was significantly lower than that of patients with caveolin-1 negative tumors (p<0.0001). The univariate analyses identified T stage, grade, and caveolin-1 expression as significant prognostic factors for cancer-specific survival, whereas the multivariate analyses indicated that T stage and caveolin-1 expression were independent prognostic factors. These results show that the increased expression of caveolin-1 is associated with tumor progression and poor prognosis in TCC-UUT, suggesting that caveolin-1 may play an important role in the progression of TCC-UUT.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 534 542 <span type="species:ncbi:9606">patients</span>
Transitional cell carcinoma of the upper urinary tract (TCC-UUT) is a relatively uncommon disease, accounting for 4.5-9% of all renal tumors and 5-6% of all urothelial tumors (1). The incidence of TCC-UUT appears to have increased recently, probably due to increased environmental exposure and aging population (2). The upper urinary tract has anatomical characteristics such as a thin muscle layer, proximity to the kidney and rich lymphatic drainage. Tumor invasion may significantly influence distant metastasis and progression in patients with TCC-UUT (3). However, the exact molecular mechanisms of tumor invasion, recurrence, progression, and prognosis of this disease remain largely unclear.
###end p 3
###begin p 4
###xml 352 353 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 464 465 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 790 791 790 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 793 794 793 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 529 534 <span type="species:ncbi:9606">human</span>
Caveolins are the major structural proteins of caveolae, the vesicular invaginations of the plasma membrane. The caveolin family includes caveolin-1, -2, and -3. Caveolin-1 and -2 are co-expressed in many cell types including adipocytes, endothelial cells, smooth muscle cells, and fibroblasts, whereas the expression of caveolin-3 is muscle-specific (4-6). Caveolin-1 has been implicated in intracellular transport, membrane trafficking, and signal transduction (5), and has also been shown to play an important role in various human pathological conditions, including cancer, diabetes, bladder dysfunction, muscular dystrophy, and those related to the cardiovascular system such as atherosclerosis, cardiac hypertrophy, cardiomyopathy, pulmonary hypertension, and neointimal hyperplasia (6, 7).
###end p 4
###begin p 5
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
The role of caveolin-1 in cancers remains controversial, because caveolin-1 has been reported to be dysregulated in various cancers, but the pattern of dysregulation appears to vary with cancer types. The caveolin-1 expression is decreased in several cancers such as ovarian carcinoma, pulmonary adenocarcinoma, various soft tissue sarcomas, and breast cancer and thought to function as a tumor suppressor gene (8-11). On the other hand, the caveolin-1 expression is upregulated in the other cancers such as renal cell carcinoma, prostate cancer, bladder cancer, colonic adenocarcinoma, and esophageal squamous cell carcinoma and associated with higher stage, cancer progression, and poor prognosis (12-17).
###end p 5
###begin p 6
###xml 189 197 <span type="species:ncbi:9606">patients</span>
There have been no previous studies about caveolin-1 expression in TCC-UUT. In the present study, therefore, we investigated the relationship between caveolin-1 expression and prognosis in patients with TCC-UUT.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and specimens
###end title 8
###begin p 9
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 107 110 <span type="species:ncbi:9606">men</span>
###xml 118 123 <span type="species:ncbi:9606">women</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
Formalin-fixed, paraffin-embedded, archival surgical specimens that had been obtained from 98 patients (76 men and 22 women; mean age of 61.7 yr, range 33-85 yr), who had been diagnosed with TCC-UUT, were assessed. All patients had undergone radical nephroureterectomy either at Ajou University Hospital or Yonsei Medical Center between November 1994 and December 2004. Tumors were staged using the 2002 TNM staging system (18) and graded according to the World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grading criteria (19).
###end p 9
###begin title 10
Immunohistochemistry
###end title 10
###begin p 11
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 286 291 <span type="species:ncbi:10090">mouse</span>
Immunohistochemical staining for the expression of caveolin-1 was carried out as previously described (12). Briefly, paraffin-embedded 4- m tissue sections were deparaffinized, treated with 3% hydrogen peroxide, followed by incubation with the blocking reagent, and then incubated with mouse monoclonal antibody against caveolin-1 (clone 2297, diluted 1:200; BD Biosciences, San Diego, CA, U.S.A.) for 1 hr at 37â„ƒ. Staining was carried out by the standard streptavidin-biotin-peroxidase complex method. Positive caveolin-1 staining of smooth muscle cells or endothelium, known to be abundant in caveolin-1, served as an internal positive control. Negative controls were obtained by omitting the primary antibody.
###end p 11
###begin title 12
Evaluation of immunohistochemical staining
###end title 12
###begin p 13
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 659 665 657 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
The immunostaining was independently evaluated by two pathologists who were unaware of the clinical data. The caveolin-1 expression was based on the presence of cytoplasmic and/or membranous staining, which was semi-quantitatively estimated according to the methods described by Sinicrope et al. (20), with minor modifications. On the basis of the percentages of immunopositive cells, the data were subdivided into five categories: 0, </=10%; 1, 11-25%; 2, 26-50%; 3, 51-75%; and 4, >75% positive cells. The immunointensity was also subclassified into four categories: 0, negative; 1, weak; 2, moderate (same intensity of smooth muscle cells); and 3, strong (Fig. 1). The immunoreactive score (caveolin-1 expression) for each case was generated by multiplying the values for the two parameters. A score of 0 was considered as negative, while all other scores were considered as positive.
###end p 13
###begin title 14
Statistical analysis
###end title 14
###begin p 15
###xml 369 370 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The correlation between caveolin-1 expression and various clinicopathological variables was analyzed by the chi-square test. The cancer-specific survival calculations were illustrated with Kaplan-Meier curves, and univariate and multivariate analyses were performed using the log-rank test and the Cox proportional hazards regression model, respectively. The values of p<0.05 were considered to be statistically significant in all of the analyses. All statistical analyses were performed using SPSS(R), version 12.0.
###end p 15
###begin title 16
RESULTS
###end title 16
###begin p 17
###xml 90 97 90 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
The clinicopathological characteristics of the 98 patients with TCC-UUT are summarized in Table 1. There were no distant metastases in any patients at the time of radical nephroureterectomy. Seventy patients were disease-free at a median follow-up of 52.5 months (range, 12-162 months). The other 28 patients developed metastases at a median of 28 months (range, 4-86 months) after radical nephroureterectomy. Twenty-seven patients died of disease during the follow-up period.
###end p 17
###begin p 18
###xml 75 82 75 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
The patterns of caveolin-1 expression in the 98 patients are summarized in Table 2. Of the 98 sections, positive immunostaining for caveolin-1 was observed in 10 sections (10.2%).
###end p 18
###begin p 19
###xml 69 70 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 121 122 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 193 194 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 243 244 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 314 321 314 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
The caveolin-1 expression was significantly correlated with T stage (p<0.001) and grade (p=0.036), but not with N stage (p=0.149), tumor location (p=0.847), previous history of bladder cancer (p=0.711), coexisting bladder cancer at diagnosis (p=0.211), or bladder cancer recurrence during the follow-up (p=0.691) (Table 3).
###end p 19
###begin p 20
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 194 200 194 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
A Kaplan-Meier survival curve showed that the survival rate of patients with caveolin-1 positive tumors was significantly lower than that of patients with caveolin-1 negative tumors (p<0.0001) (Fig. 2).
###end p 20
###begin p 21
###xml 44 45 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 100 101 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 314 321 314 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
The univariate analyses identified T stage (p<0.0001), grade (p=0.0172), and caveolin-1 expression (p<0.0001) as significant prognostic factors for cancer-specific survival, whereas the multivariate analyses indicated that T stage (p=0.036) and caveolin-1 expression (p=0.002) were independent prognostic factors (Table 4).
###end p 21
###begin title 22
DISCUSSION
###end title 22
###begin p 23
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 972 973 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 235 240 <span type="species:ncbi:9606">human</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 723 728 <span type="species:ncbi:9606">human</span>
The role of caveolin-1 in cancers still remains controversial. Several studies have suggested that caveolin-1 could function as a tumor suppressor gene. The genes encoding caveolin-1 and -2 are localized at the D7S522 locus located on human chromosome 7q31.1, a region frequently deleted in various types of human cancers (21). The allelic loss at chromosome 7q31.3 occurred in all grades and stages of invasive ovarian carcinomas, but not in borderline ovarian tumors, suggesting that the inactivation of a tumor suppressor gene in this region is an early event in ovarian tumorigenesis (22). Caveolin-1 (-/-) null mice showed acceleration of the development of dysplastic mammary lesions (23), and caveolin-1 transfected human breast cancer cell line MCF-7 cells showed less proliferation than the vector control transfectants (11). In addition, the caveolin-1 expression has been found to be down-regulated in ovarian carcinoma, pulmonary adenocarcinoma, and sarcomas (8-10). Taken together, these findings suggest that caveolin-1 has tumor suppressor characteristics.
###end p 23
###begin p 24
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 278 283 <span type="species:ncbi:9606">human</span>
###xml 327 332 <span type="species:ncbi:10090">mouse</span>
In contrast, however, several studies have shown elevated caveolin-1 expression levels in some cancers and cancer cell lines. The increased expression of caveolin-1 has been found to be associated with drug-resistant cancer cell lines, such as paclitaxel or etoposide-resistant human lung cancer cells and androgen-insensitive mouse prostate cancer cells (24-26). Furthermore, the increased caveolin-1 expression has been reported in renal cell carcinoma, prostate cancer, bladder cancer, colonic carcinoma, and esophageal squamous cell carcinoma. In many of these tumors, caveolin-1 overexpression was associated with higher tumor stage, tumor invasion, tumor size, higher grade, and poor prognosis (12-17). These findings indicate that caveolin-1 may function as a tumor promoter during carcinogenesis rather than as a tumor suppressor.
###end p 24
###begin p 25
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1318 1320 1318 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 316 321 <span type="species:ncbi:9606">human</span>
The differential expression of caveolin-1, depending on the histologic subtypes of cancers or different malignant stages, has also been reported. In the majority of small cell lung cancers, caveolin-1 expression was lost through promoter methylation, the major mode of inactivation of many tumor suppressor genes in human cancers, whereas caveolin-1 expression in the majority of non-small cell lung cancers was retained and appeared to be required for tumor growth through the activation of FAK and Ra1A signaling (27). In lung adenocarcinomas, the caveolin-1 served as a tumor suppressor with the loss of caveolin-1 regulation, resulting in tumor extension and dedifferentiation, whereas caveolin-1 overexpression in lung squamous cell carcinoma was correlated with tumor extension, suggesting that these reciprocal functions of caveolin-1 are due to different activation states of the different domains of caveolin-1 and altered interactions with binding partners (28). In oral squamous cell carcinomas, the rate of caveolin-1 immunoreactivity increased progressively from normal oral mucosa, oral pre-cancer lesions to primary carcinomas, whereas it decreased from primary to metastatic carcinomas. These findings indicated the possibility of biphasic behavior of caveolin-1 in oral carcinogenesis and metastasis (29). Therefore, caveolin-1 might function either as a tumor promoter or as a tumor suppressor, depending on the tumor cell types or malignant stages.
###end p 25
###begin p 26
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
For the expression of caveolin-1 in urothelial carcinomas, studies have been done in bladder carcinomas, but not in TCC-UUT. Rajjayabun et al. (14) found that the caveolin-1 expression was correlated with tumor stage and grade of bladder TCC, but not with tumor multiplicity, recurrence, progression, or survival of patients. Positive immunostaining for caveolin-1 was detected in 10.1% of tumor specimens. Fong et al. (15) showed that positive caveolin-1 immunostaining was detected in 37% of urothelial carcinoma, but not in nonneoplastic urothelium, and that the elevated expression of caveolin-1 and -2 was correlated with tumor grade and squamous differentiation.
###end p 26
###begin p 27
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
In the present study, we investigated the expression of caveolin-1 in TCC-UUT and found that the positive immunostaining for caveolin-1 was observed in 10.2% of sections, similar to the findings of Rajjayabun et al. (14) in bladder TCC. Furthermore, the caveolin-1 expression was correlated significantly with T stage and grade. The survival rate of patients with caveolin-1 positive tumors was significantly lower than that of patients with caveolin-1 negative tumors. Also, the caveolin-1 expression was an independent prognostic factor for cancer-specific survival. These findings strongly indicate that caveolin-1 is involved in tumor progression, and that the increased expression of caveolin-1 is a late event in urothelial carcinomas.
###end p 27
###begin p 28
In conclusion, the increased expression of caveolin-1 is associated with tumor progression and poor prognosis in TCC-UUT, suggesting that caveolin-1 may play an important role in the progression of TCC-UUT.
###end p 28
###begin title 29
ACKNOWLEDGEMENT
###end title 29
###begin p 30
We especially thank Dr. Seung Soo Shin for statistical advice.
###end p 30
###begin article-title 31
Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression
###end article-title 31
###begin article-title 32
Upper tract urothelial neoplasms: incidence and survival during the last 2 decades
###end article-title 32
###begin article-title 33
Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract
###end article-title 33
###begin article-title 34
Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane
###end article-title 34
###begin article-title 35
Multiple functions of caveolin-1
###end article-title 35
###begin article-title 36
The caveolin genes: from cell biology to medicine
###end article-title 36
###begin article-title 37
###xml 67 72 <span type="species:ncbi:9606">human</span>
Caveolae and caveolin in transmembrane signaling: implications for human disease
###end article-title 37
###begin article-title 38
###xml 32 37 <span type="species:ncbi:9606">human</span>
Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene
###end article-title 38
###begin article-title 39
Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array
###end article-title 39
###begin article-title 40
Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas
###end article-title 40
###begin article-title 41
Caveolin-1 as tumor suppressor gene in breast cancer
###end article-title 41
###begin article-title 42
Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma
###end article-title 42
###begin article-title 43
###xml 45 50 <span type="species:ncbi:9606">human</span>
Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker
###end article-title 43
###begin article-title 44
Caveolin-1 expression is associated with high-grade bladder cancer
###end article-title 44
###begin article-title 45
Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation
###end article-title 45
###begin article-title 46
Elevated expression of caveolin-1 in adenocarcinoma of the colon
###end article-title 46
###begin article-title 47
Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage
###end article-title 47
###begin article-title 48
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee
###end article-title 48
###begin article-title 49
bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis
###end article-title 49
###begin article-title 50
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 145 150 <span type="species:ncbi:9606">human</span>
Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers
###end article-title 50
###begin article-title 51
Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas
###end article-title 51
###begin article-title 52
###xml 108 123 <span type="species:ncbi:10090">transgenic mice</span>
Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice
###end article-title 52
###begin article-title 53
Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells
###end article-title 53
###begin article-title 54
Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells
###end article-title 54
###begin article-title 55
###xml 99 104 <span type="species:ncbi:10090">mouse</span>
Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells
###end article-title 55
###begin article-title 56
Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer
###end article-title 56
###begin article-title 57
###xml 47 52 <span type="species:ncbi:9606">human</span>
Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma
###end article-title 57
###begin article-title 58
The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis
###end article-title 58
###begin p 59
###xml 45 48 45 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 105 108 105 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 258 261 258 261 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 352 355 352 355 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(D)</bold>
Immunohistochemical staining for caveolin-1. (A) Cancer cells were not stained (caveolin-1 intensity 0). (B) Smooth muscle cells were stained as an internal control. Cancer cells were weakly stained, compared to an internal control (caveolin-1 intensity 1). (C) Cancer cells were stained in same intensity as internal control (caveolin-1 intensity 2). (D) Cytoplasms of cancer cells were strongly stained for caveolin-1 (caveolin-1 intensity 3). Original magnification, x400.
###end p 59
###begin p 60
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier cancer-specific survival curves according to the caveolin-1 expression. The survival rate of patients with caveolin-1 positive tumors was significantly lower than that of patients with caveolin-1 negative tumors (p<0.0001).
###end p 60
###begin p 61
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Clinicopathological data of the 98 patients included in the study
###end p 61
###begin p 62
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Pattern of caveolin-1 expression in the 98 patients
###end p 62
###begin p 63
Relationship between caveolin-1 expression and clinicopathological variables
###end p 63
###begin p 64
Univariate and multivariate survival analyses
###end p 64
###begin p 65
CI, confidence interval.
###end p 65

